• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

    5/7/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email

    BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025.



    The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale.





    Quarter Ended



    Dollars in millions, except per share data



    March 31,





    December 31,





    March 31,





    Change







    2025





    2024





    2024





    Prior Qtr





    Prior Yr.



    Revenue from Continuing Operations



    $

    143





    $

    148





    $

    136







    (3)

    %





    5

    %

    Organic growth





































    6

    %

    Sample Management Solutions



    $

    80





    $

    81





    $

    74







    (2)

    %





    8

    %

    Multiomics



    $

    64





    $

    66





    $

    62







    (4)

    %





    2

    %











































    Diluted EPS Continuing Operations



    $

    (0.40)





    $

    (0.21)





    $

    (0.29)







    (93)

    %





    (36)

    %

    Diluted EPS Total



    $

    (0.88)





    $

    (0.29)





    $

    (2.47)







    NM







    64

    %











































    Non-GAAP Diluted EPS Continuing Operations



    $

    0.05





    $

    0.08





    $

    0.06







    (43)

    %





    (23)

    %

    Adjusted EBITDA - Continuing Operations



    $

    14





    $

    13





    $

    8







    7

    %





    75

    %

    Adjusted EBITDA Margin - Continuing Operations





    10.0

    %





    9.0

    %





    6.0

    %





















    Management Comments 

    "We delivered another quarter of strong performance in an evolving and uncertain macroeconomic environment. Our performance in the second quarter and first half of our fiscal year demonstrates the resilience of our portfolio and the dedication of our teams that focus on our customers with our clearly differentiated products and services," said John Marotta, President and CEO. "We have a healthy balance sheet, and strong cash position, which provides optionality to continue investing in our long-term growth plans while maintaining our continued disciplined in capital deployment. We remain confident in our positioning and disciplined in how we operate the business while navigating these uncertain times." 

    Second Quarter Fiscal 2025 Results - Continuing Operations

    • Revenue was $143 million, up 5% year over year. Organic revenue, which excludes the impact from foreign exchange, was up 6% year over year. The year-over-year revenue increase was attributable to higher Sample Management Solutions and Multiomics revenues.
    • Sample Management Solutions revenue was $80 million, up 8% year over year.
      • Organic revenue grew 8%, mainly driven by higher revenues in Sample Repository Solutions and Core Products, particularly in Consumables and Instruments, Sample Storage, Clinical Stores and Product Services.
    • Multiomics revenue was $64 million, up 2% year over year.
      • Organic revenue grew 3% year over year, primarily driven by growth in Next Generation Sequencing, partially offset by a year-over-year decline in Sanger Sequencing and Gene Synthesis.

    Summary of GAAP Earnings Results - Continuing Operations

    • Operating loss was $16 million. Operating margin was (11.3%), up 650 basis points year over year.
      • Gross margin was 45.9%, up 140 basis points year over year, mainly driven by higher revenue, favorable sales mix and operational efficiencies.
      • Operating expenses were $82 million, down 3% year over year, primarily due to lower research and development expense and the impact of non-recurring intangible asset impairment charges recorded in the same period last year. These were partially offset by higher selling, general and administrative expenses, as well as increased restructuring and transformation charges.
    • Other income included $4 million of net interest income versus $9.5 million in the prior year period.
    • Diluted EPS from continuing operations was ($0.40) compared to ($0.29) in the second quarter of fiscal year 2024. Diluted EPS from discontinued operations was ($0.49). Total diluted EPS was ($0.88), compared to ($2.47) a year ago.

    Summary of Non-GAAP Earnings Results - Continuing Operations

    • Adjusted operating loss was $0.6 million. Adjusted operating margin was (0.4%), an improvement of 280 basis points year over year.
      • Adjusted gross margin was 47.5%, up 130 basis points compared to the second quarter of fiscal 2024, primarily driven by higher revenue, favorable sales mix and operating efficiencies.
      • Adjusted operating expense in the quarter was $69 million, up 2% year over year, primarily driven by higher selling, general and administrative expenses, partially offset by lower research and development costs.
    • Adjusted EBITDA was $14 million, and Adjusted EBITDA margin was 10.0%, an improvement of 400 basis points year over year.
    • Non-GAAP Diluted EPS was $0.05, compared to $0.06 one year ago.

    Cash and Liquidity as of March 31, 2025

    • The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $540 million, which includes $27 million of cash held in discontinued operations.
    • Operating cash flow was $14 million in the quarter. Capital expenditures were $7 million, and free cash flow (cash flow from operations less capital expenditures) was $7 million.

    Guidance for Continuing Operations for Full Year Fiscal 2025

    • The Company is reiterating its revenue guidance for fiscal year 2025:
      • Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.
      • Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.

    Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges that are not representative of the normal operations of the business.

    Conference Call and Webcast

    Azenta management will webcast its second quarter fiscal 2025 earnings conference call today at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed. 

    The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events and will be archived online on this website for convenient on-demand replay.

    Regulation G – Use of Non-GAAP financial Measures

    The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts.

    "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

    Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following: uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US, our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstance on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

    About Azenta Life Sciences

    Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

    Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

    AZENTA INVESTOR CONTACTS:

    Yvonne Perron

    Vice President, Financial Planning & Analysis and Investor Relations

    [email protected]

    Sherry Dinsmore

    [email protected]

    AZENTA, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (unaudited)

    (In thousands, except per share data)







    Three Months Ended





    Six Months Ended







    March 31,





    March 31,







    2025





    2024





    2025





    2024



    Revenue

























    Products



    $

    41,955





    $

    38,772





    $

    85,782





    $

    82,479



    Services





    101,463







    97,583







    205,146







    195,601



    Total revenue





    143,418







    136,355







    290,928







    278,080



    Cost of revenue

























    Products





    23,159







    24,015







    48,493







    50,798



    Services





    54,373







    51,676







    107,878







    104,875



    Total cost of revenue





    77,532







    75,691







    156,371







    155,673



    Gross profit





    65,886







    60,664







    134,557







    122,407



    Operating expenses

























    Research and development





    6,869







    7,733







    13,249







    15,046



    Selling, general and administrative





    71,588







    69,058







    144,801







    138,947



    Impairment of intangible assets





    —







    4,658







    —







    4,658



    Restructuring charges





    3,580







    3,428







    4,011







    4,214



    Total operating expenses





    82,037







    84,877







    162,061







    162,865



    Operating loss





    (16,151)







    (24,213)







    (27,504)







    (40,458)



    Other income

























    Interest income, net





    4,489







    9,479







    8,787







    19,434



    Other income (expense), net





    1,157







    (268)







    2,360







    250



    Loss before income taxes





    (10,505)







    (15,002)







    (16,357)







    (20,774)



    Income tax expense





    7,680







    1,200







    11,249







    2,620



    Loss from continuing operations





    (18,185)







    (16,202)







    (27,606)







    (23,394)



    Loss from discontinued operations, net of tax





    (22,271)







    (120,678)







    (26,190)







    (129,210)



    Net loss



    $

    (40,456)





    $

    (136,880)





    $

    (53,796)





    $

    (152,604)



    Basic net loss per share:

























    Loss from continuing operations



    $

    (0.40)





    $

    (0.29)





    $

    (0.60)





    $

    (0.42)



    Loss from discontinued operations, net of tax





    (0.49)







    (2.18)







    (0.57)







    (2.30)



    Basic net loss per share



    $

    (0.88)





    $

    (2.47)





    $

    (1.18)





    $

    (2.72)



    Diluted net loss per share:

























    Loss from continuing operations



    $

    (0.40)





    $

    (0.29)





    $

    (0.60)





    $

    (0.42)



    Loss from discontinued operations, net of tax





    (0.49)







    (2.18)







    (0.57)







    (2.30)



    Diluted net loss per share



    $

    (0.88)





    $

    (2.47)





    $

    (1.18)





    $

    (2.72)



    Weighted average shares used in computing net loss per share:

























    Basic





    45,732







    55,440







    45,658







    56,078



    Diluted





    45,732







    55,440







    45,658







    56,078



     

    AZENTA, INC.

    CONSOLIDATED BALANCE SHEETS

    (unaudited)

    (In thousands, except share and per share data)







    March 31,





    September 30,







    2025





    2024





















    Assets

















    Current assets















    Cash and cash equivalents



    $

    253,642





    $

    280,030



    Short-term marketable securities





    74,697







    151,162



    Accounts receivable, net of allowance for expected credit losses ($5,624 and $5,349, respectively)





    149,490







    156,273



    Inventories





    83,321







    78,923



    Short-term restricted cash





    2,102







    2,069



    Prepaid expenses and other current assets





    67,590







    75,456



    Current assets held for sale





    79,754







    88,894



    Total current assets





    710,596







    832,807



    Property, plant and equipment, net





    151,716







    155,622



    Long-term marketable securities





    176,781







    49,454



    Long-term deferred tax assets





    731







    837



    Operating lease right-of-use assets





    59,856







    60,406



    Goodwill





    682,955







    691,409



    Intangible assets, net





    111,202







    125,042



    Other assets





    7,125







    10,670



    Noncurrent assets held for sale





    140,963







    173,794



    Total assets



    $

    2,041,925





    $

    2,100,041



    Liabilities and stockholders' equity













    Current liabilities













    Accounts payable



    $

    39,155





    $

    33,344



    Deferred revenue





    41,608







    30,493



    Accrued warranty and retrofit costs





    5,237







    5,213



    Accrued compensation and benefits





    26,039







    27,785



    Accrued customer deposits





    26,318







    22,324



    Accrued income taxes payable





    10,321







    9,266



    Accrued expenses and other current liabilities





    43,102







    46,364



    Current liabilities held for sale





    28,933







    30,050



    Total current liabilities





    220,713







    204,839



    Long-term tax reserves





    417







    398



    Long-term deferred tax liabilities





    22,458







    18,084



    Long-term operating lease liabilities





    53,696







    56,683



    Other long-term liabilities





    10,062







    8,874



    Noncurrent liabilities held for sale





    33,087







    42,196



    Total liabilities





    340,433







    331,074



















    Stockholders' equity















    Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding





    —







    —



    Common stock, $0.01 par value - 125,000,000 shares authorized, 59,237,887 shares issued and 45,776,018 shares outstanding at March 31, 2025; 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024





    593







    590



    Additional paid-in capital





    520,961







    505,958



    Accumulated other comprehensive loss





    (42,149)







    (13,464)



    Treasury stock, at cost - 13,461,869 shares at March 31, 2025 and September 30, 2024





    (200,956)







    (200,956)



    Retained earnings





    1,423,043







    1,476,839



    Total stockholders' equity





    1,701,492







    1,768,967



    Total liabilities and stockholders' equity



    $

    2,041,925





    $

    2,100,041



     

    AZENTA, INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (unaudited)

    (In thousands)







    Six Months Ended March 31,







    2025





    2024



    Cash flows from operating activities

















    Net loss



    $

    (53,796)





    $

    (152,604)



    Adjustments to reconcile net loss to net cash provided by operating activities:













    Depreciation and amortization





    32,053







    44,214



    Impairment of goodwill and intangible assets





    —







    115,975



    Loss on assets held for sale





    24,187







    —



    Inventory write-downs and other asset write-offs





    4,326







    7,499



    Stock-based compensation





    13,453







    8,804



    Amortization and accretion on marketable securities





    (983)







    (2,084)



    Deferred income taxes





    (1,885)







    (9,456)



    (Gain) loss on disposals of property, plant and equipment





    (7)







    260



    Changes in operating assets and liabilities:













    Accounts receivable





    6,713







    2,922



    Inventories





    (6,030)







    8,238



    Accounts payable





    1,864







    936



    Deferred revenue





    12,042







    3,379



    Accrued warranty and retrofit costs





    343







    (714)



    Accrued compensation and tax withholdings





    (2,379)







    (7,831)



    Accrued restructuring costs





    1,548







    1,454



    Other assets and liabilities





    12,752







    1,379



    Net cash provided by operating activities





    44,201







    22,371



    Cash flows from investing activities

















    Purchases of property, plant and equipment





    (15,158)







    (19,542)



    Purchases of marketable securities





    (236,237)







    (345,447)



    Sales and maturities of marketable securities





    184,636







    190,504



    Proceeds from other investment





    2,130







    —



    Net investment hedge settlement





    3,043







    1,476



    Net cash used in investing activities





    (61,586)







    (173,009)



    Cash flows from financing activities

















    Proceeds from issuance of common stock





    1,553







    1,678



    Payments of finance leases





    (457)







    (386)



    Share repurchases





    —







    (186,834)



    Excise tax payment for settled share repurchases





    (11,376)







    —



    Net cash used in financing activities





    (10,280)







    (185,542)



    Effects of exchange rate changes on cash, cash equivalents and restricted cash





    (4,459)







    16,255



    Net decrease in cash, cash equivalents and restricted cash





    (32,124)







    (319,925)



    Cash, cash equivalents and restricted cash, beginning of period





    320,990







    684,045



    Cash, cash equivalents and restricted cash, end of period



    $

    288,866





    $

    364,120



    Supplemental disclosures:













    Cash (received) / paid for income taxes, net





    (4,594)







    5,008



    Purchases of property, plant and equipment included in accounts payable and accrued expenses





    5,773







    2,270



    Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets

















    March 31,





    September 30,







    2025





    2024



    Cash and cash equivalents of continuing operations



    $

    253,642





    $

    280,030



    Cash included in current assets held for sale





    27,025







    30,899



    Short-term restricted cash





    2,102







    2,069



    Long-term restricted cash included in other assets





    6,097







    7,992



    Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows



    $

    288,866





    $

    320,990



    Notes on Non-GAAP Financial Measures - Continuing Operations

    Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.





    Quarter Ended





    March 31, 2025





    December 31, 2024





    March 31, 2024















    per diluted













    per diluted













    per diluted



    Amounts in thousands, except per share data



    $





    share





    $





    share





    $





    share



    Net loss from continuing operations



    $

    (18,185)





    $

    (0.40)





    $

    (9,421)





    $

    (0.21)





    $

    (16,202)





    $

    (0.29)



    Adjustments:

















































    Amortization of completed technology





    2,308







    0.05







    1,500







    0.03







    2,067







    0.04



    Amortization of other intangible assets





    3,803







    0.08







    4,573







    0.10







    5,152







    0.09



    Transformation costs(1)





    5,183







    0.11







    3,046







    0.07







    4,095







    0.07



    Restructuring charges





    3,580







    0.08







    431







    0.01







    3,428







    0.06



    Impairment of intangible assets





    —







    —







    —







    —







    4,658







    0.08



    Merger and acquisition costs and costs related to share repurchase(2)





    688







    0.02







    1,570







    0.03







    426







    0.01



    Investment income(3)





    (2,130)







    (0.05)







    —







    —







    —







    —



    Tax adjustments(4)





    6,900







    0.15







    408







    0.01







    1,645







    0.03



    Tax effect of adjustments





    (40)







    (0.00)







    1,530







    0.03







    (1,959)







    (0.04)



    Non-GAAP adjusted net income from continuing operations



    $

    2,107





    $

    0.05





    $

    3,637





    $

    0.08





    $

    3,310





    $

    0.06



    Stock-based compensation, pre-tax





    8,031







    0.18







    4,872







    0.11







    5,410







    0.10



    Tax rate





    17

    %





    —







    15

    %





    —







    12

    %





    —



    Stock-based compensation, net of tax





    6,690







    0.15







    4,141







    0.09







    4,761







    0.09



    Non-GAAP adjusted net income excluding stock-based compensation - continuing operations



    $

    8,797





    $

    0.19





    $

    7,778





    $

    0.17





    $

    8,071





    $

    0.15





















































    Shares used in computing non-GAAP diluted net income per share





    —







    45,732







    —







    45,626







    —







    55,440



     





    Six Months Ended







    March 31, 2025





    March 31, 2024















    per diluted













    per diluted



    Amounts in thousands, except per share data



    $





    share





    $





    share



    Net loss from continuing operations



    $

    (27,606)





    $

    (0.60)





    $

    (23,394)





    $

    (0.42)



    Adjustments:

































    Amortization of completed technology





    3,808







    0.08







    3,923







    0.07



    Amortization of other intangible assets





    8,376







    0.18







    10,523







    0.19



    Transformation costs(1)





    8,229







    0.18







    4,136







    0.07



    Restructuring charges





    4,011







    0.09







    4,214







    0.08



    Impairment of intangible assets





    —







    —







    4,658







    0.08



    Merger and acquisition costs and costs related to share repurchase(2)





    2,258







    0.05







    4,747







    0.08



    Investment income(3)





    (2,130)







    (0.05)







    —







    —



    Tax adjustments(4)





    7,308







    0.16







    3,338







    0.06



    Tax effect of adjustments





    1,490







    0.03







    (4,288)







    (0.08)



    Non-GAAP adjusted net income from continuing operations



    $

    5,744





    $

    0.13





    $

    7,857





    $

    0.14



    Stock-based compensation, pre-tax





    12,904







    0.28







    8,411







    0.15



    Tax rate





    17

    %





    —







    12

    %





    —



    Stock-based compensation, net of tax





    10,749







    0.24







    7,402







    0.13



    Non-GAAP adjusted net income excluding stock-based compensation - continuing operations



    $

    16,493





    $

    0.36





    $

    15,259





    $

    0.27





































    Shares used in computing non-GAAP diluted net income per share





    —







    45,658







    —







    56,078



    (1)

    Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

    (2)

    Includes expenses related to governance-related matters.

    (3)

    The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature.  

    (4)

    Tax adjustments during all periods include adjustments to tax benefits related to stock compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. Tax adjustments for the three and six months ended March 31, 2025 include $6.6 million of tax expenses related to a one-time repatriation of historical earnings from China.   

     





    Quarter Ended





    Six Months Ended







    March 31,





    December 31,





    March 31,





    March 31,





    March 31,



    Dollars in thousands



    2025





    2024





    2024





    2025





    2024



    GAAP net loss



    $

    (40,456)





    $

    (13,340)





    $

    (136,880)





    $

    (53,796)





    $

    (152,604)



    Less: Loss from discontinued operations





    (22,271)







    (3,919)







    (120,678)







    (26,190)







    (129,210)



    GAAP net loss from continuing operations





    (18,185)







    (9,421)







    (16,202)







    (27,606)







    (23,394)



    Adjustments:









































    Interest income, net





    (4,489)







    (4,298)







    (9,479)







    (8,787)







    (19,434)



    Income tax expense





    7,680







    3,569







    1,200







    11,249







    2,620



    Depreciation





    7,818







    7,474







    7,395







    15,292







    14,815



    Amortization of completed technology





    2,308







    1,500







    2,067







    3,808







    3,923



    Amortization of other intangible assets





    3,803







    4,573







    5,152







    8,376







    10,523



    Earnings before interest, taxes, depreciation and amortization - Continuing operations



    $

    (1,065)





    $

    3,397





    $

    (9,867)





    $

    2,332





    $

    (10,947)



     





    Quarter Ended





    Six Months Ended







    March 31,





    December 31,





    March 31,





    March 31,





    March 31,



    Dollars in thousands



    2025





    2024





    2024





    2025





    2024



    Earnings before interest, taxes, depreciation and amortization - Continuing operations



    $

    (1,065)





    $

    3,397





    $

    (9,867)





    $

    2,332





    $

    (10,947)



    Adjustments:









































    Stock-based compensation





    8,031







    4,872







    5,410







    12,904







    8,411



    Restructuring charges





    3,580







    431







    3,428







    4,011







    4,214



    Impairment of intangible assets





    —







    —







    4,658







    —







    4,658



    Merger and acquisition costs and costs related to share repurchase(1)





    688







    1,570







    426







    2,258







    4,747



    Transformation costs(2)





    5,183







    3,046







    4,095







    8,229







    4,136



    Investment income(3)





    (2,130)







    —







    —







    (2,130)







    —



    Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations



    $

    14,287





    $

    13,316





    $

    8,150





    $

    27,604





    $

    15,219



    (1)

    Includes expenses related to governance-related matters.

    (2)

    Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

    (3)

    The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature. 

     





    Quarter Ended



    Dollars in thousands



    March 31, 2025





    December 31, 2024





    March 31, 2024



    GAAP gross profit



    $

    65,886







    45.9

    %



    $

    68,671







    46.6

    %



    $

    60,664







    44.5

    %

    Adjustments:

















































    Amortization of completed technology





    2,308







    1.6

    %





    1,500







    1.0

    %





    2,067







    1.5

    %

    Transformation costs(1)





    —







    —

    %





    52







    0.0

    %





    359







    0.3

    %

    Other adjustments





    (9)







    (0.0)

    %





    6







    0.0

    %





    —







    —

    %

    Non-GAAP adjusted gross profit



    $

    68,185







    47.5

    %



    $

    70,229







    47.6

    %



    $

    63,091







    46.3

    %

     





    Six Months Ended



    Dollars in thousands



    March 31, 2025





    March 31, 2024



    GAAP gross profit



    $

    134,557







    46.3

    %



    $

    122,407







    44.0

    %

    Adjustments:

































    Amortization of completed technology





    3,808







    1.3

    %





    3,923







    1.4

    %

    Transformation costs(1)





    52







    0.0

    %





    359







    0.1

    %

    Non-GAAP adjusted gross profit



    $

    138,417







    47.6

    %



    $

    126,689







    45.6

    %

    (1)

    Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

     





    Sample Management Solutions





    Multiomics







    Quarter Ended





    Quarter Ended







    March 31,





    December 31,





    March 31,





    March 31,





    December 31,





    March 31,



    Dollars in thousands



    2025





    2024





    2024





    2025





    2024





    2024



    GAAP gross profit



    $

    38,251







    47.9

    %



    $

    38,114







    46.9

    %



    $

    32,943







    44.4

    %



    $

    27,635







    43.5

    %



    $

    30,557







    46.1

    %



    $

    27,721







    44.6

    %

    Adjustments:

































































































    Amortization of completed technology





    1,449







    1.8

    %





    639







    0.8

    %





    1,028







    1.4

    %





    859







    1.4

    %





    861







    1.3

    %





    1,040







    1.7

    %

    Transformation costs(1)





    —







    —

    %





    52







    0.1

    %





    359







    0.5

    %





    —







    —

    %





    —







    —

    %





    —







    —

    %

    Other adjustment





    (9)







    (0.0)

    %





    5







    0.0

    %





    —







    —

    %





    —







    —

    %





    1







    —

    %





    —







    —

    %

    Non-GAAP adjusted gross profit



    $

    39,691







    49.7

    %



    $

    38,810







    47.8

    %



    $

    34,330







    46.3

    %



    $

    28,494







    44.9

    %



    $

    31,419







    47.4

    %



    $

    28,761







    46.2

    %









    Segment Total







    Quarter Ended







    March 31,





    December 31,





    March 31,



    Dollars in thousands



    2025





    2024





    2024



    GAAP gross profit



    $

    65,886







    45.9

    %



    $

    68,671







    46.6

    %



    $

    60,664







    44.5

    %

    Adjustments:

















































    Amortization of completed technology





    2,308







    1.6

    %





    1,500







    1.0

    %





    2,068







    1.5

    %

    Transformation costs(1)





    —







    —

    %





    52







    0.0

    %





    359







    0.3

    %

    Other adjustment





    (9)







    (0.0)

    %





    6







    0.0

    %





    —







    —

    %

    Non-GAAP adjusted gross profit



    $

    68,185







    47.5

    %



    $

    70,229







    47.6

    %



    $

    63,091







    46.3

    %

     





    Sample Management Solutions





    Multiomics







    Six Months Ended





    Six Months Ended



    Dollars in thousands



    March 31, 2025





    March 31, 2024





    March 31, 2025





    March 31, 2024



    GAAP gross profit



    $

    76,366







    47.4

    %



    $

    66,215







    43.2

    %



    $

    58,191







    44.8

    %



    $

    56,192







    45.0

    %

    Adjustments:

































































    Amortization of completed technology





    2,088







    1.3

    %





    1,843







    1.4

    %





    1,720







    1.3

    %





    2,080







    1.7

    %

    Transformation costs(1)





    52







    0.0

    %





    359







    0.3

    %





    —







    —

    %





    —







    —

    %

    Non-GAAP adjusted gross profit



    $

    78,506







    48.7

    %



    $

    68,417







    44.7

    %



    $

    59,911







    46.2

    %



    $

    58,272







    46.6

    %

     





    Segment Total







    Six Months Ended



    Dollars in thousands



    March 31, 2025





    March 31, 2024



    GAAP gross profit



    $

    134,557







    46.3

    %



    $

    122,407







    44.0

    %

    Adjustments:

































    Amortization of completed technology





    3,808







    1.3

    %





    3,923







    1.4

    %

    Transformation costs(1)





    52







    0.0

    %





    359







    0.1

    %

    Non-GAAP adjusted gross profit



    $

    138,417







    47.6

    %



    $

    126,689







    45.6

    %

    (1)

    Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

     





    Sample Management Solutions





    Multiomics







    Quarter Ended





    Quarter Ended







    March 31,





    December 31,





    March 31,





    March 31,





    December 31,





    March 31,



    Dollars in thousands



    2025





    2024





    2024





    2025





    2024





    2024



    GAAP operating income (loss)



    $

    567





    $

    1,562





    $

    (2,894)





    $

    (6,132)





    $

    (3,387)





    $

    (3,920)



    Adjustments:

















































    Amortization of completed technology





    1,449







    639







    1,028







    859







    861







    1,040



    Amortization of other intangible assets





    —







    13







    52







    —







    —







    —



    Transformation costs(1)





    2,606







    103







    359







    —







    —







    —



    Restructuring charges





    —







    —







    —







    (23)







    23







    —



    Other adjustments





    (9)







    —







    (2)







    —







    —







    —



    Non-GAAP adjusted operating income (loss)



    $

    4,613





    $

    2,317





    $

    (1,457)





    $

    (5,296)





    $

    (2,503)





    $

    (2,880)



     





    Total Segments





    Corporate





    Total







    Quarter Ended





    Quarter Ended





    Quarter Ended







    March 31,





    December 31,





    March 31,





    March 31,





    December 31,





    March 31,





    March 31,





    December 31,





    March 31,



    Dollars in thousands



    2025





    2024





    2024





    2025





    2024





    2024





    2025





    2024





    2024



    GAAP operating income (loss)



    $

    (5,565)





    $

    (1,825)





    $

    (6,814)





    $

    (10,586)





    $

    (9,528)





    $

    (17,399)





    $

    (16,151)





    $

    (11,353)





    $

    (24,213)



    Adjustments:









































































    Amortization of completed technology





    2,308







    1,500







    2,068







    —







    —







    (1)







    2,308







    1,500







    2,067



    Amortization of other intangible assets





    —







    13







    52







    3,803







    4,560







    5,100







    3,803







    4,573







    5,152



    Transformation costs(1)





    2,606







    103







    359







    2,577







    2,943







    3,736







    5,183







    3,046







    4,095



    Restructuring charges





    (23)







    23







    —







    3,603







    408







    3,428







    3,580







    431







    3,428



    Impairment of intangible assets





    —







    —







    —







    —







    —







    4,658







    —







    —







    4,658



    Merger and acquisition costs and costs related to share repurchase(2)





    —







    —







    —







    688







    1,570







    426







    688







    1,570







    426



    Other adjustments





    (9)







    —







    (2)







    —







    9







    2







    (9)







    9







    —



    Non-GAAP adjusted operating income (loss)



    $

    (683)





    $

    (186)





    $

    (4,337)





    $

    85





    $

    (38)





    $

    (50)





    $

    (598)





    $

    (224)





    $

    (4,387)



     





    Sample Management Solutions





    Multiomics







    Six Months Ended





    Six Months Ended



    Dollars in thousands



    March 31,





    March 31,





    March 31,





    March 31,







    2025





    2024





    2025





    2024



    GAAP operating income (loss)



    $

    2,129





    $

    (4,380)





    $

    (9,519)





    $

    (8,223)



    Adjustments:

































    Amortization of completed technology





    2,088







    1,843







    1,720







    2,080



    Amortization of other intangible assets





    —







    103







    —







    —



    Transformation costs(1)





    2,709







    359







    —







    —



    Other adjustments





    4







    2







    3







    (1)



    Non-GAAP adjusted operating income (loss)



    $

    6,930





    $

    (2,073)





    $

    (7,796)





    $

    (6,144)



     





    Total Segments





    Corporate





    Total







    Six Months Ended





    Six Months Ended





    Six Months Ended



    Dollars in thousands



    March 31,





    March 31,





    March 31,





    March 31,





    March 31,





    March 31,







    2024





    2024





    2025





    2024





    2025





    2024



    GAAP operating loss



    $

    (7,390)





    $

    (12,603)





    $

    (20,114)





    $

    (27,855)





    $

    (27,504)





    $

    (40,458)



    Adjustments:

















































    Amortization of completed technology





    3,808







    3,923







    —







    —







    3,808







    3,923



    Amortization of other intangible assets





    —







    103







    8,376







    10,420







    8,376







    10,523



    Transformation costs(1)





    2,709







    359







    5,520







    3,777







    8,229







    4,136



    Restructuring charges





    —







    —







    4,011







    4,214







    4,011







    4,214



    Impairment of intangible assets





    —







    —







    —







    4,658







    —







    4,658



    Merger and acquisition costs and costs related to share repurchase(2)





    —







    —







    2,258







    4,747







    2,258







    4,747



    Other adjustments





    7







    1







    (7)







    (2)







    —







    (1)



    Non-GAAP adjusted operating income (loss)



    $

    (866)





    $

    (8,217)





    $

    44





    $

    (41)





    $

    (822)





    $

    (8,258)



    (1)

    Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.

    (2)

    Includes expenses related to governance-related matters.

     





    Sample Management Solutions





    Multiomics





    Azenta Total







    Quarter Ended





    Quarter Ended





    Quarter Ended







    March 31,





    March 31,













    March 31,





    March 31,













    March 31,





    March 31,











    Dollars in millions



    2025





    2024





    Change





    2025





    2024





    Change





    2025





    2024





    Change



    Revenue



    $

    80





    $

    74







    8

    %



    $

    64





    $

    62







    2

    %



    $

    143





    $

    136







    5

    %

    Currency exchange rates





    0







    —







    1

    %





    1







    —







    1

    %





    1







    —







    1

    %

    Organic revenue



    $

    80





    $

    74







    8

    %



    $

    64





    $

    62







    3

    %



    $

    144





    $

    136







    6

    %

     





    Sample Management Solutions





    Multiomics





    Azenta Total







    Six Months Ended





    Six Months Ended





    Six Months Ended







    March 31,





    March 31,













    March 31,





    March 31,













    March 31,





    March 31,











    Dollars in millions



    2025





    2024





    Change





    2025





    2024





    Change





    2025





    2024





    Change



    Revenue



    $

    161





    $

    153







    5

    %



    $

    130





    $

    125







    4

    %



    $291





    $

    278







    5

    %

    Currency exchange rates





    0







    —







    0

    %





    1







    —







    0

    %





    1





    —







    0

    %

    Organic revenue



    $

    161





    $

    153







    5

    %



    $

    130





    $

    125







    4

    %



    $

    292





    $278







    5

    %











































































     

    Azenta logo (PRNewsfoto/Azenta)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-reports-second-quarter-results-for-fiscal-2025-ended-march-31-2025-302448232.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Financials

    Live finance-specific insights

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

      BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui

      2/5/25 7:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Azenta upgraded by Stephens with a new price target

      Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

      12/18/24 7:25:24 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Jefferies initiated coverage on Azenta with a new price target

      Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00

      4/4/24 7:29:19 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • B. Riley Securities reiterated coverage on Azenta with a new price target

      B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously

      2/1/24 8:17:35 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO and Treasurer Lin Lawrence Y. was granted 2,200 units of Common, increasing direct ownership by 6% to 37,513 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/13/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Koffey Quentin was granted 4,040 shares, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:48:51 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Malus Alan J was granted 4,040 units of Common, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:10:12 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Azenta Inc.

      SC 13G/A - Azenta, Inc. (0000933974) (Subject)

      11/13/24 4:05:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: SEC Form SC 13D/A filed by Azenta Inc.

      SC 13D/A - Azenta, Inc. (0000933974) (Subject)

      11/4/24 8:41:47 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form SC 13G filed by Azenta Inc.

      SC 13G - Azenta, Inc. (0000933974) (Subject)

      10/31/24 11:55:02 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    SEC Filings

    See more
    • Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/7/25 7:05:31 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      4/9/25 4:30:57 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      2/10/25 5:19:29 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report

      BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024. The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmental Protection: We understand the broad impact of our operations and the potential to impact the world. We are committed to evaluating ways to reduce our environmental footprint while continu

      3/24/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

      NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

      11/19/24 5:56:00 PM ET
      $AZTA
      $CON
      $ENV
      $FLEX
      Industrial Machinery/Components
      Technology
      Medical Specialities
      Health Care
    • Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

      William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

      11/4/24 8:00:00 AM ET
      $AZTA
      $BV
      $LVWR
      Industrial Machinery/Components
      Technology
      Business Services
      Consumer Discretionary
    • AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

      Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

      9/4/24 8:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/4/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:16 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:11 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology